Amati Global Investors

Manufacture 2030 is a digital platform with first mover advantage. They’re on a mission to slash resource use in global manufacturing by 2030. They’ve built a cloud-based tool called M2030 bee that helps manufacturers increase profits by cutting operational costs and environmental impacts.

Flylogix specializes in the development of advanced unmanned aircraft designed for efficient over-horizon operations. The company provides a range of services, including maritime surveillance, oil spill response, airspace management, methane emissions monitoring, and unmanned logistics. By leveraging these technologies, Flylogix aims to deliver essential information from remote environments, thereby enabling businesses to enhance operational effectiveness while reducing carbon emissions and improving safety. The company's innovative approach offers cost-effective solutions for industries facing challenges in remote operations.

eleXsys Energy operates as a cleantech energy company. eleXsys Energy’s innovative technology unlocks the full potential of electricity networks, by providing services that enable a two way flow of electricity on grids

eleXsys Energy operates as a cleantech energy company. eleXsys Energy’s innovative technology unlocks the full potential of electricity networks, by providing services that enable a two way flow of electricity on grids

Amryt Pharma is a biopharmaceutical company focused on developing and commercializing innovative treatments for patients with serious and life-threatening rare diseases. The company offers several commercial products, including Myalept, which is used as an adjunct to diet for treating complications related to leptin deficiency in patients with generalized lipodystrophy, and Lojuxta, a medication for adults with homozygous familial hypercholesterolemia. Additionally, Amryt is advancing its development candidates, such as FILSUVEZ, aimed at treating cutaneous manifestations of epidermolysis bullosa, and AP103, a pre-clinical gene therapy for recessive dystrophic epidermolysis bullosa. Established in 2015 and headquartered in London, Amryt Pharma markets its products in the Americas, Europe, and the Middle East, focusing on addressing high unmet medical needs in rare and orphan diseases.